A useful way to understand Exemestane is to start with the biology it targets. Irreversibly inactivates aromatase, reducing estrogen synthesis. The therapeutic effect is tied to estrogen or other hormone signaling, so receptor status, menopausal context, and disease setting help define its place in treatment. The database classifies it as Hormonal / Endocrine Therapy; Aromatase Inhibitor and associates it with Breast Cancer. Its principal oncology indications are HR-positive breast cancer in postmenopausal patients, including adjuvant and advanced/metastatic settings. Depending on the disease, the agent may appear as a single-agent treatment, a component of combination therapy, or part of a defined treatment sequence. The documented regimen examples are Exemestane monotherapy; exemestane + everolimus. The database places it within endocrine management, where the hormonal environment and disease state are important determinants of clinical use. This distinction matters because treatment selection is not determined simply by the presence of a cancer diagnosis; the tumor subtype, disease stage, previous therapy, and molecular or receptor characteristics can narrow the appropriate setting. Unlike nonsteroidal aromatase inhibitors in the database, this entry identifies a steroidal aromatase inhibitor, while retaining a postmenopausal hormone-receptor-positive breast-cancer focus. The pharmacology helps explain its individual position among related medicines. Current labeling and the applicable oncology guideline should be consulted when the database is used for clinical reference.